The Growth Stack: CJC-1295 + Ipamorelin vs MK-677 — Pulse vs Plateau

After the Wolverine stack or the GLP-1 experience, the second stack almost every founder-operator runs is something in the growth hormone axis. The choice tends to be CJC-1295 + Ipamorelin or MK-677. It gets settled by brand allegiance or the first YouTube video that loads.

The video gives you the mechanism in the first two minutes. It does not give you the selection framework. It does not tell you which receptor pattern is doing the physiological work, why the water-retention signal from MK-677 is structural rather than adjustable, or what the IGF-1 response curve looks like on each approach over a 12-week block.

If Issue 5 was the repair arc — tissue remodeling, recovery signal — this is the growth arc. Same operator, next protocol question. The half-life math from Issue 3 is the substrate: CJC-1295 is the long-half-life worked example from that issue; Ipamorelin is its short-half-life complement. MK-677 sits on its own pharmacokinetic axis. The framework holds: mechanism first, half-life second, receptor pattern third, decision last.

Three different entry points. Same downstream target: IGF-1.

CJC-1295 (with DAC) is a GHRH analog. It binds the GHRH receptor on somatotroph cells in the anterior pituitary and triggers GH release. The DAC modification — Drug Affinity Complex — extends the half-life from roughly 30 minutes (CJC-1295 without DAC, also called Mod-GRF 1-29) to approximately 6–8 days. The result: sustained GHRH receptor stimulation over days, not minutes. GH accumulates progressively across a cycle as CJC-1295 reaches steady state at roughly five half-lives — the same steady-state math from Issue 3 applied here.

Ipamorelin is a GHRP — growth hormone releasing peptide. It binds the ghrelin receptor (GHSR-1a) on pituitary somatotrophs and drives a GH pulse. Half-life is approximately 2 hours. The selectivity profile is one of Ipamorelin's defining characteristics: minimal cortisol or prolactin elevation compared to older GHRPs like GHRP-6. The standard pairing with CJC-1295 is mechanistically grounded — the GHRH receptor and the GHSR-1a receptor operate on different signaling axes, and stimulating both simultaneously produces a synergistic GH pulse larger than either alone. This is the Thorner synergy principle: pulsatile GH release is amplified when two distinct receptor pathways converge on the somatotroph at the same time.

MK-677 (Ibutamoren) is an oral ghrelin mimetic. It also binds GHSR-1a — the same receptor as Ipamorelin — but it is orally bioavailable and acts for roughly 24 hours after a single dose. No reconstitution, no injection. Once-daily pill. The operational simplicity is real. The pharmacokinetic consequence of that simplicity is the entire issue.

This is the central decision node.

The pulse argument (CJC + Ipa): The pituitary's native GH release is pulsatile. Sharp spikes, mostly during slow-wave sleep, followed by rapid clearance and receptor reset. That pattern is what the GHSR-1a receptor was designed for. CJC-1295's long half-life keeps a GHRH signal present continuously across the accumulation phase; Ipamorelin amplifies the GH pulse only at the moment of administration. The combined protocol lets an operator synchronize the GHRP administration with the natural pre-sleep spike rather than permanently saturating the receptor. Issue 3's steady-state framework applies directly: CJC-1295 accumulates across a cycle; Ipamorelin does not. That asymmetry gives the operator more precise control over pulse frequency and timing than any once-daily oral compound can provide.

The plateau argument (MK-677): MK-677 keeps GHSR-1a stimulated continuously across a 24-hour window. IGF-1 rises and stays elevated — a plateau rather than a pulse. The plateau is operationally easier to manage: one pill, no injection schedule, no reconstitution. The tradeoff is pharmacokinetic. Continuous GHSR-1a stimulation is not the native receptor pattern. The literature on MK-677's long-term GH axis effects — primarily the Nass et al. Phase 2 trial and subsequent community aggregation — shows more operator-to-operator variability in GH output than the pulsatile GHRP approach. The most cited operator complaint is persistent water retention. That complaint is not a titration-speed artifact. It is the compound's steady-state doing exactly what the mechanism predicts.

The output metric both approaches share is IGF-1. Elevated GH drives liver IGF-1 synthesis, and circulating IGF-1 rises across weeks of sustained GH stimulation regardless of the delivery pattern.

CJC + Ipa: IGF-1 rises progressively over a 12-week block as CJC-1295 accumulates toward steady state. The sleep impact is mechanistically directional. The clinical literature on GHRH analogs in older subjects documents improved slow-wave sleep — the GH release that normally concentrates in Stage 3 declines significantly with age, and GHRH analog administration partially restores the pulsatile amplitude that drives that Stage 3 signal. Pre-sleep Ipamorelin timing is consistent with that finding: delivering a GHRP pulse at the window where the natural sleep-GH spike would occur gives the somatotroph two aligned inputs at the physiologically relevant moment.

MK-677: Nass et al. — the Phase 2 RCT in older adults — documented IGF-1 elevation of 40–70% above baseline at 12 months of daily MK-677 use. That is Tier 1 data. The study also documented sleep architecture effects: subjects reported vivid dreams and, in some cases, lighter overall sleep quality in the first 4–6 weeks of use, with attenuation of that signal after the adjustment period. The sleep variability from MK-677 is the largest operator-reported divergence from the CJC + Ipa experience. Some operators tolerate it and find it normalizes; others do not and switch mid-cycle. The Nass trial enrolled older adults; extrapolation to a 35–50-year-old founder-operator population is Tier 2 by definition, not Tier 1.

Set the mechanism aside for one section.

MK-677's water-retention effect is predictable, dose-consistent, and present in the clinical literature. The Nass Phase 2 trial listed edema as a common adverse event in the active arm. Operator and community reports cluster the scale-weight addition at 3–8 lbs in weeks 1–4 of use. That water weight is real, not a lean-mass gain. For an operator running a body-composition protocol with visible feedback — training photos, DEXA follow-up, weekly scale data — the water-retention signal makes the feedback loop noisy. You cannot separate the scale-weight response attributable to lean tissue from the scale-weight response attributable to fluid retention without a DEXA measurement, and DEXA cadence rarely matches the pace of the operator's subjective protocol tracking.

CJC + Ipa does not produce the same sustained GHSR-1a stimulation pattern. Ipamorelin's short half-life means the receptor engages and clears; there is no continuous fluid-retention signal analogous to MK-677's 24-hour receptor occupation. That difference in water-retention signal matters more to most operators than the receptor-activation theory. It is the criterion that actually determines which protocol an operator stays on past week four.

Three questions. No protocol.

1. Oral vs. injectable? MK-677 wins on operational ease. CJC + Ipa wins on GH-pulse timing control. For a researcher unwilling or unable to reconstitute and inject, MK-677 is the orally-bioavailable alternative in this category.

2. Body-composition feedback without water-noise? CJC + Ipa. The water-retention variable from MK-677 degrades the measurement signal on the timescale most operators actually use for self-assessment. If visible body-composition progress — without ambiguity about fluid dynamics — is the primary feedback mechanism, MK-677 introduces a confound CJC + Ipa does not.

3. Sleep quality as a primary endpoint? The CJC + Ipa stack as commonly described in the literature pairs pre-sleep GHRP administration with the Stage 3 GH signal. MK-677 is the alternative for IGF-1 elevation without injection, if the vivid-dream adjustment phase (4–6 weeks in the Nass data) is acceptable. If sleep is already fragile, the MK-677 adjustment period is a real cost.

That is the tree. Three nodes, no brand allegiance required.

The evidence base is asymmetric between the two approaches, and that asymmetry matters.

MK-677: The Nass et al. Phase 2 trial is Tier 1 — a randomized controlled trial in older adults, 12 months, with IGF-1, lean mass, and adverse-event data. The 40–70% IGF-1 elevation figure and the edema signal are both from that trial. The Bengtsson group's MK-677 work in GH-deficient adults provides a second Tier 1 data point on IGF-1 response. This is the best-evidenced oral GH-axis compound in the RUO category at the human RCT level.

CJC-1295 + Ipamorelin (as a stack): The CJC-1295 without DAC and Ipamorelin individual compounds have Tier 3 mechanistic data and some human pharmacokinetic work in the GHRH-analog literature. The Thorner group's synergy work on GHRH + GHRP co-administration is the mechanistic anchor for the two-receptor amplification model. The CJC-1295 with DAC + Ipamorelin stack specifically — the combination as it is actually run by operators — has not been tested in a controlled human trial. The evidence base for the combined protocol is Tier 3 (mechanistic) and Tier 4 (community aggregation and practitioner reports). That distinction is load-bearing: MK-677 has Tier 1 human RCT data; the CJC + Ipa stack does not.

State the evidence asymmetry plainly and let the operator weigh it.

The pulse-vs-plateau choice is the selection criterion the community papers over with brand allegiance. MK-677 is operationally simpler and has better human RCT evidence than the CJC + Ipa stack. CJC + Ipa gives more control over pulsatile timing and skips the water-retention signal that degrades the body-composition feedback loop. Neither produces results without a serious training program and adequate protein. The MK-677 literature is Tier 1 in older adults; the CJC + Ipa stack specifically is Tier 3 and Tier 4.

Issue 08 — Cognitive Peptides for Founders Who Don't Want a Modafinil Habit: Selank, Semax, and What the Russian Literature Actually Shows. Founder n=1 eight-week trial: intranasal Selank AM, Semax pre-deep-work. What the Soviet-era clinical data established, and what the operator community has extrapolated beyond it.

Colby

For research use only. Not medical advice. Compounds discussed are sold for research purposes; nothing here is a recommendation to use them on humans or animals. The publisher of The Compound has a financial interest in heroxbio.com, an RUO peptide vendor; this relationship may influence which compounds are covered. See the About page for full disclosure.